Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

Yifei Zhang 1, Yanyun Gu 1, Huahui Ren 2, Shujie Wang 1, Huanzi Zhong 2, Xinjie Zhao 3, Jing Ma 4, Xuejiang Gu 5, Yaoming Xue 6, Shan Huang 7, Jialin Yang 8, Li Chen 9, Gang Chen 10, Shen Qu 11, Jun Liang 12, Li Qin 13, Qin Huang 14, Yongde Peng 15, Qi Li 3, Xiaolin Wang 3, Ping Kong 2, Guixue Hou 2, Mengyu Gao 2, Zhun Shi 2, Xuelin Li 1, Yixuan Qiu 1, Yuanqiang Zou 2, Huanming Yang 2 16, Jian Wang 2 16, Guowang Xu 3, Shenghan Lai 17, Junhua Li 18 19, Guang Ning 1, Weiqing Wang 20

Main idea: the study reports a human microbial related mechanism underlying the antidiabetic effect of BBR on T2D

Abstract

Human gut microbiome is a promising target for managing type 2 diabetes (T2D) Measures altering gut microbiota like oral intake of probiotics or berberine (BBR), a bacteriostatic agent, merit metabolic homoeostasis. We conducted a randomized, double-blind, placebo-controlled trial with newly diagnosed T2D patients from 20 centres in China. The changes in glycated haemoglobin, as the primary outcome, were significantly greater in the probiotics+BBR group than in the placebo and BBR-alone group. BBR treatment induced more gastrointestinal side effects than gentamycin pretreatment.

Source NIH